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Abstract 
Background: Our purpose is to examine the relationship of Health related quality of life measured by EORTC 
QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer 
(LC) patients were, included in this national multicenter Project entitled of “the LC Quality of Life Project (AKAYAK). 
Baseline scores were analyzed by using Cox’s proportional hazard regression to identify factors that influenced sur-
vival. Univariate and multivariate models were run for each of the scales included in the study.
Results: Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; 
symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for 
age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of 
the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical function-
ing and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically 
significant after adjustment. LC13 and LCSS scales were not predictors of survival.
Conclusions: HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. 
Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instru-
ments for this purpose.
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Background
Health-related quality of life (HRQOL) (Coates et  al. 
1997) domains have been valued mainly when survival 
gain in clinical trials remains unanswered (Dancey et al. 
1997), but its use is very restrictive for clinical decision 
making (Vigano et al. 2004).
Lung cancer (LC) is one of the common cancers in 
men worldwide, and survival, treatment modalities, 
and HRQOL of LC patients are issues that need to 
be addressed in a clinical context. It is both an impor-
tant and difficult task for clinicians to predict progno-
sis in cancer patients and especially for patients having 
advanced lung cancer. Until recent decades, health pro-
fessionals used objective performance indicators in a 
dominant role to predict the prognosis of lung cancer. 
Several studies have shown the ability of HRQOL instru-
ments to predict survival based on different cancer sites 
(Coates et al. 1997; Dancey et al. 1997; Vigano et al. 2004; 
Gotay et al. 2008; Quinten et al. 2009, 2014; Grande et al. 
2009; Montazeri et  al. 2001; Li et  al. 2012; Langendijk 
et  al. 2000; Efficace et  al. 2006; Maione et  al. 2005; 
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Herndon et  al. 1999; Polanski et  al. 2016; Ganz et  al. 
1991; Eton et  al. 2003; Bernhard et  al. 1996; Dharma-
Wardene et  al. 2004; Reck et  al. 2012; Hwang et  al. 
2004; Sloan et al. 2012; Qi et al. 2009; Kaasa et al. 1989; 
Naughton et  al. 2002; Nowak et  al. 2004; Braun et  al. 
2011; Nishiyama et al. 2006; Movsas et al. 2009). These 
studies, either reviews (Gotay et al. 2008; Mannion et al. 
2014; Guyatt et al. 1993) or longitudinal design studies, 
found that baseline HRQOL was a prognostic indicator 
of survival. In their recent review, Mannion et al. (2014) 
stated that the European Organisation for Research 
and Treatment of Cancer-Quality of Life Questionnaire 
(QLQ-C30) was the most widely used questionnaire; 
other commonly used scales include the Functional 
Assessment of Cancer Therapy-Lung (FACT-L) and the 
Lung Cancer Symptom Scale (LCSS). Although there is 
a consensus on the assessment of HRQOL in predicting 
survival in LC patients, it is still unclear which of these 
instruments better predicts survival. Until recently, there 
have been very few studies that aimed to compare differ-
ent HRQOL instruments with regard to their ability to 
predict survival in LC patients. Only one study (Grande 
et al. 2009) used generic QOL measurement tools to pre-
dict survival of patients having lung cancer. A disease-
specific measure may provide more detailed outcome 
information and so may be more relevant to patients and 
clinicians (Guyatt et al. 1993), although it was stated that 
the overall impact of functioning and well-being may be 
missed by using only a disease-specific measure (Coons 
and Shaw 2005).
The objective of this study was to examine the prognos-
tic value of baseline HRQOL for survival in any type of 
LC using well-known self-assessment tools of HRQOL in 
lung cancer. To our knowledge, this multi-centre study 
conducted the first analyses of QOL as a prognostic fac-
tor for survival among patients having all types of lung 
cancer, by using of a battery of different generic, cancer- 




This study was performed within the framework of a 
national multi-centre project entitled “The Lung Cancer 
Quality of Life Project” (AKAYAK-1). We contacted 299 
LC patients undergoing active chemotherapy, surgery, or 
post-therapy follow-up from April 2010 to February 2012 
in an inpatient setting or at the outpatient clinics of five 
comprehensive cancer centres in western Turkey
HRQOL and performance scales were completed at 
baseline for all patients regardless of the treatment type 
(chemotherapy, radiotherapy or a combination).
During these visits, HRQOL instruments were applied to 
the patients via interviewer assistance and the Karnofsky 
performance status (KPS) and Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (Oken et al. 1982) 
were also assessed for all patients by nurses/physicians.
Compliance with ethical standards
The AKAYAK project has obtained an ethical approval by 
the Research Ethics Committee of Ege University, Izmir, 
Turkey. The authors of this manuscript have no affilia-
tions with or involvement in any organization or entity 
with any financial interest, or non-financial in the sub-
ject matter or materials discussed in this manuscript. No 
funding was received for this study.
Patients
The inclusion criteria for the patients (n =  299) in this 
trial were as follows:
  • Patients who were diagnosed with Primary LC as 
stage IIIB or IV (including all histological types).
  • Age between 18 and 76 years.
  • Previously untreated and planning to undergo chem-
otherapy, radiotherapy, or chemo-radiotherapy.
  • Ability to read and complete questionnaires,
  • Agreed to participate in the study and volunteer to 
attend the control visits.
  • Written informed consent form was provided.
HRQOL scales and variables examined
HRQOL scales
“The European Organisation for  Research and  Treat‑
ment of  Cancer Quality of  Life Questionnaire (EORTC 
QLQ‑C30)” “EORTC QLQ-C30 consists of 30 items 
assessing global HRQOL. These items are grouped into 
five functional scales, including physical functioning, role 
functioning, emotional functioning, cognitive function-
ing and social functioning; into three symptom scales 
including fatigue, nausea and vomiting, and pain; and six 
single-item scales including dyspnoea, insomnia, appetite 
loss, constipation, diarrhoea, and financial difficulties” 
(Aaronson et al. 1993). A validated (Guzelant et al. 2004) 
Turkish version of the QLQ-C30 was used in this study.
“EORTC Lung Cancer Scale (QLQ‑LC 13)” “The QLQ 
Lung Cancer module (QLQ-LC13) consists of 13 ques-
tions assessing lung cancer-associated symptoms (cough, 
haemoptysis, dyspnoea, and site-specific pain), treatment-
related side effects (sore mouth, dysphagia, peripheral 
neuropathy, and alopecia), and pain medication” (Berg-
man et al. 1994). QLQ LC13 was validated into Turkish by 
Ataman et al. (2008).
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Functional assessment of  cancer therapy‑lung cancer 
(FACT‑L)” Turkish version of the FACT-L was devel-
oped by Basarik (2011). FACT-L is a combination of a 
generic cancer scale, the Functional Assessment of Can-
cer Therapy-Generic (FACT-G) and a lung cancer sub-
scale (LCS), and consists of 37 questions (Cella et al. 1993, 
1995). Generic subscales and the item compositions of 
FACT-G are as follows: Physical Well-Being (seven items), 
Social/Family Well-Being (seven items), Emotional Well-
Being (six items), and Functional Well-Being (seven 
items). The 10-item LCS assesses LC symptoms. The Trial 
Outcome Index (TOI) is a 21-item single-score scale that 
sums the PWB, EWB, and LCS subscales of the FACT-L, 
proposed to assess the physical components of HRQOL. 
Total possible scores range between 0 and 84, with higher 
scores indicating a better QOL” (Cella et al. 1995).
Lung Cancer Symptom Scale (LCSS) The LCSS evaluates 
six major symptoms associated with lung malignancies 
and their effects on overall symptomatic distress, func-
tional activities, and global QOL. Physical and functional 
dimensions are assessed by five items, and an average of 
the aggregate score of all nine items is defined as the total 
score (Hollen et al. 1995). Korkmaz and Fadiloglu (2007), 
developed and validated Turkish version of the LCSS in 
2007.
EuroQoL (EQ5‑D) EQ  5-D was developed as a five 
dimension preference-based measure of HRQOL (Euro-
Qol_Group 1990). In this study, we used the validated 
Turkish version (Eser et al. 2007) of the index.
Prognostic clinical variables
Tumour characteristics, such as histology, tumour type, 
stage, duration of illness, type of treatment, and patient 
characteristics, including age, gender, education, and 
co-morbidities at the time of diagnosis, were obtained. 
All histological types were included in our study. The 
7th edition of lung cancer TNM classification and stag-
ing system was used in this study (http://www.uicc.org/
resources/tnm/publications-resources).
Statistical analyses
Baseline HRQOL and performance assessments were 
used for predicting survival in this study. Initially, the 
scales of the QLQ C-30, LC-13, FACT-L, and LCSS were 
categorised according to tertiles, whereas the single-item 
symptom scales of QLQ C-30 and EQ5-D dimensions 
were dichotomised. In univariate Cox analysis, baseline 
HRQOL scores were used as independent variables to 
assess the crude risk of survival separately for each scale. 
A multivariate Cox’s regression analysis was performed 
by adjusting baseline scores on global QOL for known 
prognostic factors such as age, gender, clinical stage, and 
co-morbidities.
In addition to this multivariate analysis that only 
adjusted for the effects of these known prognostic fac-
tors, we examined six multivariate models indicating the 
relative hazards for survival for demographic and clinical 
variables and HRQOL scales. The model A showed the 
relative hazard for survival for only the demographic and 
clinical variables that were found significant in the uni-
variate analyses. In the model B, the functioning scales 
of the QLQ C30 that were found significant in the uni-
variate analyses which were examined simultaneously 
by adjusting for the demographic and clinical variables 
entered into the model A. “The model C” differed from 
the second by entering the symptom scales of the QLQ 
C30, instead of the functioning scales of the QLQ C30. 
In the model D, we combined models B and C. In the 
model E, the relative hazards of survival were estimated 
simultaneously for significant dimensions of the Eq5-D 
by controlling demographic and clinical variables. Finally, 
the FACT-L scales that were found to be significant in 
the univariate analyses were examined in the final model 
(Model F).
Survival curves were estimated using the Kaplan–
Meier method. The log-rank test was used to determine 
the statistical significance of the differences between 
curves. The level of significance was set at 0.05. Statistical 
analyses were performed using the SPSS software (ver-
sion 15.0 for PC).
Results
All patients (n = 299) had TNM system stage III (38.5 %) 
or IV (61.5 %) disease and an ECOG performance status 
of 0 or 1 (70.9  %) at baseline (Table  1). Univariate haz-
ard ratios (HR) indicated shorter survivals for female 
gender (HR 1.74, 95 % CI 1.06–2.85); higher stage (stage 
IV) (HR 2.13, 95 % CI 1.64–2.77); distant metastasis (HR 
1.68, 95 % CI 1.31–2.15); presence of co-morbidities (HR 
1.49, 95 % CI 1.16–1.91); non-surgery treatment experi-
ences (chemotherapy: HR 1.35, 95 % CI 1.02–1.80; radio-
therapy: HR 2.11, 95  % CI 1.44–3.08; adjuvant therapy: 
HR 2.89, 95  % CI 1.60–5.22); and patients who did not 
undergo pneumonectomy/lobectomy (HR 3.55, 95  % CI 
1.13–11.18). Age, the level of education, and tumour type 
had no significant impact on survival.
Tables  2, 3 and 4 show the results of univariate and 
multivariate analyses: In Table  2, global QOL, physi-
cal functioning, role functioning scales, and symptom 
scales for fatigue, insomnia, appetite loss, and constipa-
tion from QLQ-C30 were associated with survival after 
adjustment. None of the scales of the QLQ-LC13 or the 
index or symptom scores of LCSS showed a significant 
effect on survival even in univariate analyses (Table 3).
Page 4 of 11Eser et al. SpringerPlus  (2016) 5:1833 
Table  4 presents the results of FACT-L, EQ-5D, and 
ECOG. Physical well-being, functional well-being, LC 
scales, and the TOI score of the FACT-L had significant 
impacts on survival, but the physical scale lost its lin-
ear trend after adjustment. Moreover, the meaningful 
impacts of FACT-L and FACT-G scores on survival dis-
appeared after adjustment. All dimensions of EQ-5D, 
except the mood dimension, had an impact on survival 
after adjustment for age, gender, clinical stage, and 
co-morbidities. However, categorised EQ-5D utility and 
VAS scores showed no effect on survival. The ECOG per-
formance status was the strongest predictor of survival 
even after adjustment (HR 2.01, 95 % CI 1.54–2.64).
Hierarchical Cox proportional hazard models are 
presented in Table  5. The results for model A indicated 
that male gender, younger age (<50 years), stage IV, and 
co-morbidities were predictors of worse survival. The 
physical function scale (model B) and the constipation 
symptom scale (model C) of the QLQ-C30 were sig-
nificant prognostic factors for survival. In model D, the 
physical function scale of QLQ-C30 lost its impact on 
survival, whereas constipation symptom items remained 
a significant predictor of survival. Model E included 
EQ-5D dimensions in addition to demographic and clini-
cal variables. The dimensions of mobility and usual activ-
ities of the EQ-5D were found to be strong predictors of 
subsequent survival after adjustment for demographic 
and clinical variables.
 Survival curves represent meaningful results in the 
final reduced regression models: In Fig. 1, Kaplan–Meier 
curves indicate subgroups defined by the QLQ-C30 Con-
stipation scale, and the log-rank test indicated significant 
differences between the subgroups (P < 0.001). Figure 1 
presents the survival curves of the TOI score categories 
of the FACT-L, which also showed significant differ-
ences among the three TOI categories by a log-rank test 
(P < 0.001). Finally, the dimensions of mobility and usual 
activities of the EQ-5D subgroups are presented in Fig. 1, 
indicating meaningful (P  <  0.001) subgroup differences 
between the three dimensional categories.
Discussion
This study evaluated almost all of the HRQOL tools 
widely used to assess patient/clinical reported outcomes 
for their ability to forecast subsequent survival in LC 
patients.
Before interpreting the effect of HRQOL on sur-
vival, we can say that our results confirmed the predic-
tive effects of some known variables on survival, such 
as gender and cancer stage. Worse survival in males is 
consistent with the results of Quinten et al. (2014), Effi-
cace et al. (2006), Naughton et al. (2002), and Braun et al. 
(2011). Although only two stages of cancer (stage 3b and 
4) were included in this study, LC stage remained a sig-
nificant predictor of survival in all models. These results 
are also consistent with several previous studies (Quinten 
et al. 2009; Montazeri et al. 2001; Langendijk et al. 2000; 
Maione et al. 2005; Braun et al. 2011). Our findings also 
confirmed the dominant predictive value of performance 
status (measured here by the ECOG) on survival, as 
reported by many previous studies (Coates et  al. 1997; 
Langendijk et al. 2000; Efficace et al. 2006; Maione et al. 
Table 1 The relation to  demographic and  illness related 
characteristics of Lung Cancer patients to survival time
* P < 0.05; ** P < 0.01; *** P < 0.001
Variables N (%) HR (95 % CI)
Gender
 Male 23 (7.7) 1.74 (1.06–2.85)*
 Female 276 (92.3) 1.00
Age (years)
 <50 36 (12.0) 1.00
 50 ≤ Age < 60 114 (38.1) 0.94 (0.63–1.40)
 60 ≤ Age < 70 101 (33.8) 1.13 (0.76–1.69)
 ≥70 48 (16.1) 1.53 (0.97–2.41)
Education
 İlliterate–primary 223 (75.1) 1.00
 Secondary and over 74 (24.9) 0.83 (0.63–1.09)
Type of cancer
 Adenocarcinoma 69 (23.2) 1.00
 Squamous cell 110 (36.9) 0.95 (0.69–1.31)
 Small cell 61 (20.5) 0.84 (0.58–1.21)
 Other 58 (19.5) 1.21 (0.84–1.76)
Clinical stage
 Stage 3B 115 (38.5) 1.00
 Stage 4 184 (61.5) 2.13 (1.64–2.77)***
Distant metastasis
 Yes 156 (52.2) 1.68 (1.31–2.15)***
 No 139 (46.5) 1.00
Comorbidity
 Yes 103 (34.4) 1.49 (1.16–1.91)**
 No 196 (65.6) 1.00
Pneumectomy/lobectomy
 Yes 10 (3.3) 1.00
 No 289 (96.7) 3.55 (1.13–11.18)*
Chemotherapy
 Yes 230 (76.9) 1.35 (1.02–1.80)*
 No 69 (23.1) 1.00
Adjuvan therapy
 Yes 19 (6.4) 2.89 (1.60–5.22)***
 No 280 (93.6) 1.00
Radiotherapy
 Yes 35(11.7) 2.11 (1.44–3.08)
 No 264 (88.3) 1.00
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2005; Herndon et  al. 1999; Bernhard et  al. 1996; Sloan 
et  al. 2012; Qi et  al. 2009; Kaasa et  al. 1989), even after 
adjustment for demographic variables and LC stage (HR 
2.01, 95 % CI 1.54–2.64).
We found that the presence of any comorbidity was a 
predictor of worse survival, in contrast to the findings 
of a phase III Italian study (Maione et  al. 2005), which 
found no significant effect of comorbidities on survival. 
We assessed comorbidities simply by counting comorbid 
illnesses, without using any weighted measure, and this 
may have caused an underestimation of the effect of 
comorbidities on survival.
Baseline global QOL, physical functioning and role 
functioning scales and symptom scales for fatigue, 
insomnia, appetite loss, and constipation of QLQ-C30 
were found to be statistically significant prognostic fac-
tors for overall survival in patients with LC in this study. 
QLQ-C30 physical functioning and constipation scores 
Table 2 Significance of QLQ-C30 scores for overall survival of the lung cancer patients (Univariate and mulitvariate Cox’s 
regression results)
* P < 0.05; ** P < 0.01; *** P < 0.001
a Adjusted for age, gender, clinical stage (as TNM), and comorbidiy
Variables Mean (SD) N Crude HR (95 % CI) Adjusted HRa (95 % CI)
Global QoL (≥66.67 as reference) 57.6 134 1.00 1.00
50.00 > GL ≤ 66.66 (24.3) 84 1.09 (0.79–1.52) 1.02 (0.73–1.43)
≤50,00 81 1.57 (1.17–2.12)*** 1.39 (1.03–1.88)*
Physical functioning (≥86.67 as reference) 70.4 115 1.00 1.00
66.66 > PF ≤ 86.66 (27.7) 102 1.27 (0.93–1.75) 1.11 (0.80–1.54)
≤66.65 82 2.09 (1.53–2.85)*** 1.65 (1.19–2.29)**
Role functioning (≥100.0 as reference) 70.7 151 1.00 1.00
66.66 > RF ≤ 99.99 (32.4) 22 1.39 (0.87–2.21) 1.32 (0.81–2.16)
≤66.65 126 1.56 (1.21–2.02)** 1.36 (1.04–1.78)*
Emotional functioning (≥91.66 as reference) 77.8 103 1.00 1.00
66.66 > EF ≤ 91.65 (23.3) 97 1.16 (0.86–1.56) 1.28 (0.95–1.74)
≤66.65 99 1.06 (0.78–1.42) 0.98 (0.72–1.34)
Cognitive functioning (≥100.0 as reference) 86.5 72 1.00 1.00
83.33 > CF ≤ 99.99 (18.6) 59 1.18 (0.86–1.62) 1.08 (0.78–1.48)
≤83.32 168 1.29 (0.97–1.73) 1.19 (0.87–1.61)
Social functioning (≥100.0 as reference) 74.7 131 1.00 1.00
66.66 > SF ≤ 99.99 (31.6) 21 1.26 (0.78–2.04) 1.22 (0.75–2.00)
≤66.65 147 1.13 (0.88–1.45) 0.99 (0.77–1.429)
Fatigue (=0 as reference) 43.1 36 1.00 1.00
>0 (28.8) 263 2.08 (1.39–3.11)*** 1.73 (1.14–2.61)**
Pain (=0 as reference) 36.3 79 1.00 1.00
>0 (31.2) 220 1.31 (0.99–1.72) 1.10 (0.82–1.47)
Nausea/vomiting (=0 as reference) 11.1 213 1.00 1.00
>0 (21.6) 86 1.16 (0.89–1.51) 1.13 (0.86–1.49)
Dyspnoea (=0 as reference) 34.1 110 1.00 1.00
>0 (32.8) 188 1.33 (1.03–1.71)* 1.22 (0.94–1.58)
Insomnia (=0 as reference) 32.4 120 1.00 1.00
>0 (33.3) 178 1.66 (1.29–2.14)*** 1.44 (1.10–1.88)**
Appetite loss (=0 as reference) 36.2 110 1.00 1.00
>0 (34.9) 189 1.40 (1.10–1.80)** 1.42 (1.10–1.84)**
Constipation (=0 as reference) 20.6 179 1.00 1.00
>0 (29.6) 120 1.54 (1.21–1.97)** 1.61 (1.25–2.07)***
Diarrhoea (=0 as reference) 8.9 249 1.00 1.00
>0 (22.4) 50 1.27 (0.92–1.74) 1.14 (0.82–1.57)
Financial difficulties (=0 as reference) 29.3 146 1.00 1.00
>0 (34.6) 153 1.14 (0.89–1.45) 0.99 (0.77–1.27)
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were the strongest predictors of survival in the final 
reduced model. The findings of this analysis were con-
sistent with those presented in other reports using QLQ-
C30 as a predictor of survival (Coates et al. 1997; Quinten 
et  al. 2009, 2014; Grande et  al. 2009; Montazeri et  al. 
2001; Li et al. 2012; Langendijk et al. 2000; Efficace et al. 
2006; Maione et  al. 2005; Herndon et  al. 1999; Polan-
ski et al. 2016; Naughton et al. 2002; Nowak et al. 2004; 
Nishiyama et al. 2006).
Nowak et  al. (2004) and Braun et  al. (2011) reported 
the strongest effect of physical performance on HRQOL 
among seven studies (Coates et  al. 1997; Quinten et  al. 
2009, 2014; Grande et  al. 2009; Herndon et  al. 1999; 
Nowak et al. 2004) that found the physical domain to be 
a prognostic factor for survival. The physical function 
was also reported as a strong predictor of survival in a 
study by Eton et al. (2003), who used FACT-L as a tool of 
HRQOL.
Our findings confirmed the prognostic ability of the 
global QOL score of the QLQ-C30 on overall survival 
(OS), as several studies have demonstrated in advanced 
LC patients, although some results have been contradic-
tory. In the study by Herndon et al., for example, global 
QOL was not found prognostic for survival. As Qi et al. 
(2009) noted, the inclusion of global QOL in the same 
model with other subscales may lead to multicollinear-
ity, which may be responsible for the inconsistency in the 
findings. In order to account for this problem we used a 
different multivariate model. In our model we assessed 
the global QOL score independent from other scales of 
the QLQ-C30.
We found the fatigue, appetite loss, insomnia, and 
constipation symptom scales of the QLQ-C30 to be sig-
nificant predictors of survival after adjustment in our 
study. When the generic scales of the QLQ-C30 were 
included in the models, the constipation scale remained 
Table 3 Significance of  EORTC QLQ-L13 and  LCSS scores for  overall survival of  the lung cancer patients (Univariate 
and mulitvariate Cox’s regression results)
* P < 0.05; ** P < 0.01; *** P < 0.001
a Adjusted for age, gender, clinical stage (as TNM), and comorbidiy
Variables
LC13
Mean (sd) N Crude HR (95 % CI) Adjusted HRa (95 % CI)
Dispnoea (ref = 0) 30.5 235 1.00 1.00
>0 (25.7) 64 0.83 (0.61–1.12) 1.01 (1.00–1.01)
Cough (ref = 0) 39.6 220 1.00 1.00
>0 (32.1) 79 0.93 (0.71–1.22) 1.00 (1.00–1.01)
Hemoptysis (ref = 0) 9.9 67 1.00 1.00
>0 (21.0) 232 1.01 (0.75–1.34) 1.00 (1.00–1.01)
Sore Mouth (ref = 0) 5.8 40 1.00 1.00
>0 (16.3) 259 1.14 (0.79–1.63) 1.00 (0.99–1.01)
Dysphagia (ref = 0) 9.0 54 1.00 1.00
>0 (21.4) 245 0.88 (0.64–1.21) 1.01 (1.00–1.01)
Peripheral neuropathy (ref = 0) 14.0 83 1.00 1.00
>0 (26.3) 216 0.98 (0.75–1.29) 1.01 (1.00–1.01)
Hair loss (ref = 0) 5.9 28 1.00 1.00
>0 (25.7) 269 1.40 (0.91–2.14) 1.00 (0.99–1.00)
Chest pain (ref = 0) 24.5 149 1.00 1.00
>0 (29.7) 150 0.85 (0.67–1.08) 1.00 (1.00–1.01)
Pain in arm or shoulder (ref = 0) 18.1 108 1.00 1.00
>0 (27.7) 191 0.96 (0.74–1.23) 1.00 (1.00–1.01)
Other pain sites (ref = 0) 20.7 186 1.00 1.00
>0 (16.2) 113 1.07 (0.83–1.36) 1.00 (0.99–1.01)
LCSS (Lung Cancer Symptom Scale)
 LCSS index score (30.00 ≤ as reference) 40.5 96 1.00 1.00
30.01 > LCSS.I ≤ 45.99 (20.6) 99 0. 77(0.57–1.05) 0.82 (0.60–1.21)
≥46.00 101 1.16 (0.86–1.55) 1.06 (0.78–1.42)
 LCSS symptom score (27.00 ≤ as reference) 38.1 98 1.00 1.00
27.01 > LCSS.S ≤ 43.69 (21.7) 96 0.74 (0.54–1.00) 0.76 (0.56–1.04)
≥43.70 102 1.20 (0.90–1.62) 1.12 (0.83–1.52)
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Table 4 Significance of  FACT-L, EQ-5D and  ECOG scores for  overall survival of  the lung cancer patients (Univariate 
and mulitvariate Cox’s regression results)
* P < 0.05; ** P < 0.01; *** P < 0.001
a Adjusted for age, gender, clinical stage (as TNM), and comorbidiy
b A combination of Physical (PWB), Functional (FWB) wellbeing and Lung Cancer Scale (LCS)
Variables
FACT-L
Mean (SD) N Crude HR (95 % CI) Adjusted HRa (95 % CI)
Physical (ref = ≥ 23.00) 18.9 90 1.00 1.00
15 > PWB ≤ 22 (6.2) 108 1.37 (1.02–1.84)* 1.21 (0.89–1.63)
≤15 101 1.83 (1.34–2.48)*** 1.42 (1.03–1.94)*
Social/Family (ref = ≥ 27.00) 23.5 67 1.00 1.00
20.0 > SWB ≤ 26.99 (4.8) 138 1.19 (0.90–1.57) 1.07 (0.80–1.42)
≤20 94 1.34 (0.73–2.46) 1.37 (0.75–2.54)
Emotional (ref = ≥ 21.00) 17.7 94 1.00 1.00
15 > EWB ≤ 20 (5.3) 94 1.17 (0.87–1.56) 0.97 (0.71–1.33)
≤15 110 1.07 (0.80–1.44) 1.02 (0.75–1.37)
Functional (ref = ≥ 20.00) 17.0 88 1.00 1.00
13 > FWB ≤ 19 (6.3) 90 1.07 (0.80–1.43) 1.12 (0.83–1.51)
≤13 121 1.51 (1.13–2.02)** 1.51 (1.13–2.02)*
Lung Cancer Subscale (ref = ≥ 21.00) 18.7 89 1.00 1.00
15 > LCS ≤ 20 (5.3) 93 0.88 (0.66–1.18) 0.88 (0.66–1.18)
≤15 117 1.52 (1.14–2.03)** 1.42 (1.05–1.92)**
FACT-L (ref = ≥ 105.1) 95.8 97 1.00 1.00
86.99 > FACT-L ≤ 105.1 (20.1) 99 1.20 (0.89–1.61) 1.09 (0.80–1.47)
≤86.99 102 1.63 (1.21–2.19)** 1.31 (0.96–1.79)
FACT-L TOİb (ref = ≥ 23.00) 54.7 94 1.00 1.00
15 > TOI ≤ 22 (15.2) 103 1.25 (0.93–1.67) 1.18 (0.88–1.59)
≤15 102 1.70 (1.26–2.29)** 1.45 (1.07–1.98)*
FACT-G (ref: ≥ 85.00) 77.1 99 1.00 1.00
46.99 > FACT-G ≤ 62 (16.8) 92 1.32 (0.98–1.74) 1.23 (0.91–1.66)
≤46.99 107 1.61 (1.20–2.16)** 1.29 (0.95–1.76)
Equation5-D
 Mobility (3 as reference) 186 1.00 1.00
 1 + 2 113 4.29 (2.67–6.90)*** 3.38 (2.05–5.26)***
 Self-care (3 as reference) 242 1.00 1.00
 1 + 2 57 4.38 (2.14–8.98)*** 3.30 (1.56–6.98)**
 Usual activities (3 as reference) 167 1.00 1.00
 1 + 2 132 1.68 (1.22–2.30)** 1.96 (1.41–2.72)***
 Pain (3 as reference) 127 1.00 1.00
 1 + 2 172 1.57 (1.07–2.98)* 1.51 (1.03–2.23)*
 Mood (3 as reference) 194 1.00 1.00
 1 + 2 105 1.11 (0.61–2.04) (0.54–1.86)
Equation5-D Index (1.0 as reference) 0.65 149 1.00 1.00
 Median value ≥ Index < 1.0 (0.36) 61 1.26 (0.89–1.77) 1.06 (0.75–1.51)
 <Median value 89 1.24 (0.94–1.65) 1.27 (0.95–1.62)
Equation5-D VAS (≥79.00 as reference) 65.5 101 1.00 1.00
 50.01 > VAS ≤ 78.99 (20.5) 95 1.24 (0.92–1.67) 1.19 (0.83–1.51)
 ≤50.00 102 1.40 (1.04–1.87)* 1.17 (0.86–1.60)
ECOG (Ecog 0 − 1 as reference) 212 1.00 1.00
 ECOG (value 2 + 3 + 4) 87 2.10(1.62–2.73)*** 2.01(1.54–2.64)***
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as a unique independent significant predictor of OS. Our 
findings are consistent with previous reports for appetite 
loss (Quinten et al. 2009; Grande et al. 2009; Li et al. 2012; 
Herndon et  al. 1999; Polanski et  al. 2016) and fatigue 
(Coates et al. 1997; Montazeri et al. 2001; Li et al. 2012; 
Herndon et  al. 1999; Polanski et  al. 2016; Nowak et  al. 
2004) but not for pain (Quinten et al. 2009, 2014; Li et al. 
2012; Efficace et al. 2006; Nowak et al. 2004) or dyspnoea 
(Coates et  al. 1997; Grande et  al. 2009; Herndon et  al. 
1999; Nowak et  al. 2004), which have been found to be 
significant predictors of OS that were not confirmed in 
our study. No evidence was reported for insomnia in 
previous work, and just one study (Polanski et  al. 2016) 
showed an effect of constipation, which is consistent with 
our results.
The physical and functional well-being and LCS of 
FACT-L were independently significant in the final 
reduced models, which already accounted for the effects 
of age, gender, clinical stage (TNM), and comorbidities. 
Eaton et al. (2003) evaluated FACT-L for its sensitivity on 
Table 5 Contribution of baseline sociodemographic, clinical and quality of life variables for prediction of survival in lung 
cancer patients
* P < 0.05; ** P < 0.01
PF Physical functioning, RF role functioning, FA fatigue, SL sleep problem, AP apetite loss, CO constipation, Pwb physical wellbeing, Fwb functional wellbeing, LCS Lung 
Cancer Scale
Variables entered Model A Model B Model C Model D Model E Model F
Male (ref: femalef ) 1.95 (1.18–3.22)** 2.07 (1.25–3.43)** 2.16 (1.3–3.59)** 2.21 (1.33–3.67)** 1.87 (1.13–3.09)* 1.9 (1.13–3.18)*
Age ref: < 50
 50 ≤ Age < 60 0.76 (0.48–1.22) 0.82 (0.54–1.24) 0.86 (0.54–1.39) 0.89 (0.55–1.44) 0.80 (0.53–1.21) 0.75 (0.46–1.2)
 60 ≤ Age < 70 0.64 (0.45–0.92)* 0.91 (0.59–1.4) 0.66 (0.46–0.95)* 0.68 (0.47–0.99)* 0.94 (0.62–1.42) 0.64 (0.44–0.92)*
 ≥70 0.72 (0.5–1.03) 1.17 (0.72–1.89) 0.74 (0.52–1.07) 0.75 (0.52–1.09) 1.09 (0.68–1.76) 0.66 (0.46–0.96)*
 Stage 4 (ref: 3b) 2.05 (1.57–2.68)** 1.83 (1.39–2.42)** 1.85 (1.4–2.45)** 1.75 (1.32–2.33)** 2.13 (1.62-2.82)** 1.94 (1.47–2.55)**
 Comorbidity 1.35 (1.04–1.74)* 1.35 (1.04–1.75)* 1.39 (1.07–1.8)* 1.45 (1.11–1.89)** 1.28 (0.98–1.68) 1.38 (1.06–1.8)*
QLQ-C30
 PF(ref: ≥ 86.67) 1.00 1.00
 66.66 > PF ≤ 86.66 1.05 (0.74–1.49) 0.88 (0.6–1.29)
 PF ≤ 66.65 1.52 (1.03–2.24)* 1.24 (0.81–1.88)
 RF(ref: ≥ 100.0) 1.00 1.00
 66.66 > RF ≤ 99.99 1.14 (0.83–1.57) 1.03 (0.75–1.42)
 RF ≤ 66.65 1.26 (0.76–2.07) 1.36 (0.81–2.28)
 FA 1.34 (0.84–2.13) 1.34 (0.8–2.26)
 SL 1.23 (0.92–1.65) 1.22 (0.9–1.65)
 AP 1.1 (0.82–1.48) 1.08 (0.79–1.47)
 CO 1.49 (1.14–1.93)** 1.5 (1.15–1.98)**
EQ-5D
 Mobility 3.03 (1.65–5.56)**
 Selfcare 0.98 (0.39–2.43)
 Usual activities 1.76 (1.19–2.61)**
 Pain 0.97 (0.62–1.53)
 Mood 0.79 (0.42–1.5)
FACT-L
 Pwb (ref: ≥ 23.00) 1.00
 15 > Pwb ≤ 22 1.24 (0.81–1.91)
 Pwb ≤ 15 1.18 (0.83–1.67)
 Fwb (ref: ≥ 20.00) 1.00
 13 > Fwb ≤ 19 1.24 (0.84–1.84)
 Fwb ≤ 13 1.04 (0.74–1.48)
 LCS (ref: ≥ 21.00) 1.00
 15 > LCS ≤ 20 1.09 (0.76–1.57)
 LCS ≤ 15 0.7 (0.51–0.97)*
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subsequent survival in LC patients in a longitudinal study 
and found the physical well-being scale to be predic-
tive of survival, consistent with our findings. In a second 
study by Qi et  al. (2009) using the FACT-L, weight loss 
was found to be the only significant predictor of worse 
survival and the remaining scales were not predictive. 
One finding of our study was that LCS had a predictive 
ability for worse survival when adjusted by demographic 
and clinical variables, but for longer survival in the final 
reduced model, which might be due to an inadequate 
sample size or a colinearity issue when entered into 
the same model with physical and functional scales. 
This is why we did not enter TOI in model F, since TOI 
combines the physical, functional, and LCscales of the 
FACT-L. Thus, we did not construct an additional mul-
tivariate model for TOI score or for ECOG, because they 
are already presented as the adjusted HRs in Table 4.
As previously confirmed in many studies (Langendijk 
et al. 2000; Efficace et al. 2006; Maione et al. 2005; Hern-
don et  al. 1999; Bernhard et  al. 1996; Reck et  al. 2012; 
Sloan et al. 2012; Qi et al. 2009; Kaasa et al. 1989; Movsas 
et al. 2009), performance status, assessed by ECOG, was 
a strong predictor of OS in our study, even after adjust-
ment, indicating the validity of our results.
To our knowledge, our study is the first to forecast 
subsequent survival using the EQ-5D on OS in can-
cer patients. All five dimensions of EQ-5D, except the 
“mood” dimension, were significantly sensitive to sub-
sequent survival in this study even after adjustment. 
When they were entered into the same multivariate 
model (model E), the pain and self-care dimensions were 
excluded from the final reduced model, leaving mobility 
and usual activities dimensions as strong independent 
predictors of survival. These two dimensions remained 
in the model because both refer to “physical independ-
ence,” as already confirmed by the findings of QLQ-C30 
and FACT-L in this study. In fact, Jang et al. (2010) dem-
onstrated that QLQ-C30 data could be used to derive 
EQ-5D utility scores in their study, but EQ-5D findings 
differed from those of others by their very high HRs, indi-
cating EQ-5D dimensions as important predictors of OS.
In this study, we included a battery of HRQOL instru-
ments to evaluate predictors of survival. Among them, 
none of the LC13 scales or LCSS index or symptom 
scores were found to be predictive of survival. These 
results are consistent with findings in previous studies 
(LC13: Montazeri et al. 2001; Li et al. 2012; Polanski et al. 
2016; Nowak et al. 2004, LCSS: Qi et al. 2009).
This study has some limitations. One is that this study 
merged all types of lung cancer, and the findings could 
not be expressed purely for any specific type of lung can-
cer. Second, we could not use the “duration of cancer” 
variable in this study, because most of the patients were 
newly diagnosed, but this may be strength of the study 
Fig. 1 Survival curves
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too. A third limitation was the lack of FLIC scale in the 
questionnaire battery, due to the unavailability of a vali-
dated Turkish version (Ganz et al. 1991). Finally, we could 
not run stratified analyses of the treatment arms due to 
the sample size, so the conclusions of this study may not 
be generalisable to all types of LC or treatments.
Conclusions
HRQOL serves as an additional predictive factor for sur-
vival that supplements ‘traditional’ clinical factors, such 
as age, gender, stage, and comorbidity in LC patients. 
Besides the strong predictive ability of the ECOG perfor-
mance status on survival, FACT-L and the Eq5D were the 
most promising QOL instruments for the purpose in this 
study.
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